Kamada Is Bringing Relief To Those With Rare And Serious Conditions

By Johnny Rice Benzinga

DETROIT, MICHIGAN - April 16, 2025 (NEWMEDIAWIRE) - Amir London, CEO of Kamada Pharmaceuticals (NASDAQ: KMDA), was recently a guest on Benzingas All-Access.

Kamada is a global biopharmaceutical company with a portfolio of assets indicated for rare and serious conditions. The company reports it is a leader in the specialty plasma-derived field, focused on diseases with limited treatment alternatives.

Mr. London was on the program to discuss exciting developments in the companys development pipeline as well as Mr. Londons strategy for M&A.

Watch the full interview here:

https://youtu.be/qcXRR2EqZx0

Featured photo by Hal Gatewood on Unsplash .

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

This content was originally published on Benzinga . Read further disclosures here.

Copyright 2025 JCN Newswire . All rights reserved.

You May Also Be Interested In

• BitTorrent Ushers in Next-Gen Web3 Infrastructure with Strategic Rebrand and Inaugural BTT Burn
• Arlo’s Organization Portal Gives Business Clients Their Own View of Private Training
• PERPETUAL SALES INC. (PSVQ) Outlines Its Vision for Smart Retail